GlaxoSmithKline Pharmaceuticals Intrinsic Value
GLAXO Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1326.16 | ₹1060.93 - ₹1591.39 | -46.1% | EPS: ₹60.28, Sector P/E: 22x |
| Book Value Method | asset | ₹491.96 | ₹442.76 - ₹541.16 | -80.0% | Book Value/Share: ₹115.44, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹737.94 | ₹664.15 - ₹811.73 | -70.0% | Revenue/Share: ₹240.47, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹983.92 | ₹885.53 - ₹1082.31 | -60.0% | EBITDA: ₹1488.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1036.83 | ₹829.46 - ₹1244.20 | -57.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹737.94 | ₹664.15 - ₹811.73 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹931.33 | ₹838.20 - ₹1024.46 | -62.1% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1229.90 | ₹1106.91 - ₹1352.89 | -50.0% | ROE: 52.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹737.94 | ₹664.15 - ₹811.73 | -70.0% | EPS: ₹60.28, BVPS: ₹115.44 |
Want to compare with current market value? Check GLAXO share price latest .
Valuation Comparison Chart
GLAXO Intrinsic Value Analysis
What is the intrinsic value of GLAXO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of GlaxoSmithKline Pharmaceuticals (GLAXO) is ₹931.33 (median value). With the current market price of ₹2459.80, this represents a -62.1% variance from our estimated fair value.
The valuation range spans from ₹491.96 to ₹1326.16, indicating ₹491.96 - ₹1326.16.
Is GLAXO undervalued or overvalued?
Based on our multi-method analysis, GlaxoSmithKline Pharmaceuticals (GLAXO) appears to be trading above calculated value by approximately 62.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.53 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.11 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 52.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 34.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.99x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for GlaxoSmithKline Pharmaceuticals
Additional stock information and data for GLAXO
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,290 Cr | ₹1,267 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹582 Cr | ₹582 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹484 Cr | ₹484 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹811 Cr | ₹608 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹578 Cr | ₹578 Cr | Positive Free Cash Flow | 8/10 |